chst10 Antibody

What is CHST10 and what are its primary biological functions?

CHST10 is a carbohydrate sulfotransferase that transfers sulfate to glucuronic acid, creating the HNK-1 antigen carried by glycoproteins and glycolipids primarily in neurons and NK cells . Beyond its role in forming the HNK-1 carbohydrate antigen, CHST10 has been identified as an enzyme capable of transferring sulfate to glucuronidated steroid hormones, including estrogen and testosterone . This sulfation activity provides a previously unrecognized regulatory mechanism for steroid hormone bioactivity. CHST10 is a Golgi apparatus membrane protein with a calculated molecular weight of 42 kDa (356 amino acids), though it is commonly observed at approximately 57 kDa in experimental settings . The protein contains a single-pass type II membrane domain and plays roles in neurodevelopment, synaptic plasticity, and reproductive biology through its sulfotransferase activity .

What cellular and tissue expression patterns are characteristic of CHST10?

CHST10 is primarily localized to the Golgi apparatus membrane as a single-pass type II membrane protein . Antibody studies have successfully detected CHST10 in several human cell lines and tissues. Western blot experiments consistently demonstrate CHST10 expression in BxPC-3 pancreatic cancer cells . Immunohistochemistry has revealed positive CHST10 expression in human gliomas tissue . In mouse models, CHST10 functionality has been confirmed in brain tissues through the presence of the HNK-1 antigen, which is eliminated in CHST10-null mice . Additionally, CHST10 plays significant roles in reproductive tissues, with its absence causing morphological abnormalities in female reproductive organs, particularly in the uterine endometrium . The protein's expression across multiple species (human, mouse, and rat) makes it a valuable target for comparative studies in developmental biology and endocrinology .

What are the recommended experimental applications for CHST10 antibodies?

Based on validated research protocols, CHST10 antibodies have demonstrated utility in several experimental applications:

For Western blotting, CHST10 is typically observed at approximately 57 kDa, which differs from its calculated molecular weight of 42 kDa . This discrepancy may result from post-translational modifications or protein-specific migration characteristics. For immunohistochemistry applications with human gliomas tissue, antigen retrieval with TE buffer (pH 9.0) is suggested, though citrate buffer (pH 6.0) can serve as an alternative . It is advisable to optimize antibody concentrations for each specific experimental system to achieve optimal results, as antibody performance can be sample-dependent .

How does CHST10 regulate steroid hormone activity in reproductive systems?

CHST10 plays a critical role in steroid hormone regulation through a two-step modification process. Initially, steroid hormones are glucuronidated by glucuronyltransferases associated with ER membranes . Subsequently, CHST10 transfers sulfate to these glucuronidated steroids, effectively creating doubly-conjugated hormones that exhibit altered receptor binding capacity .

In CHST10-deficient mice, the absence of this sulfation step leads to elevated serum estrogen levels, particularly at the pro-estrus stage . This hormonal dysregulation manifests as enlarged uteri with thickened endometrial tissue in female CHST10-null mice, indicating enhanced estrogen activity . Estrogen-response element reporter assays have demonstrated that CHST10-modified estrogen likely cannot bind to its receptor, suggesting that sulfation of glucuronidated estrogen represents an inactivation mechanism .

This regulatory pathway appears to function across multiple steroid hormones, as CHST10 can transfer sulfate to glucuronidated forms of estrogen, testosterone, and other steroids . The identification of this novel regulatory mechanism has significant implications for understanding hormonal homeostasis, particularly in reproductive biology. Researchers investigating steroid hormone regulation should consider CHST10-mediated sulfation as a potentially important post-translational modification affecting hormone bioavailability and activity.

What phenotypes are observed in CHST10-deficient models?

Studies of CHST10-deficient mice have revealed several distinct phenotypes with implications for neurobiology and reproductive function:

Interestingly, different targeting approaches for CHST10 knockout have yielded varying phenotypic severity. While a previously reported knockout targeting the second exon produced viable and fertile mice with cognitive deficits, the more recent knockout strategy targeting exon 5 (containing the RDP sequence in the catalytic domain) resulted in stronger phenotypes including subfertility . This difference might arise from the potential formation of a truncated protein fragment from exons 1-4 that could function as a dominant negative for other sulfotransferases .

These observations highlight the multifunctional nature of CHST10 across physiological systems and suggest that researchers should carefully consider targeting strategies when designing knockout models for this gene.

How can discrepancies between predicted and observed molecular weights of CHST10 be addressed?

The discrepancy between CHST10's calculated molecular weight (42 kDa) and its commonly observed weight in Western blotting (57 kDa) represents a methodological consideration requiring careful interpretation. Several factors may contribute to this difference:

• Post-translational modifications: CHST10 may undergo glycosylation or other modifications that increase its apparent molecular weight. As a glycosyltransferase residing in the Golgi, CHST10 itself may be subject to glycosylation.

• Protein conformation: The three-dimensional structure of CHST10 may affect its migration rate in SDS-PAGE.

• Technical variables: Gel percentage, running buffer composition, and electrophoresis conditions can all influence protein migration.

To address these discrepancies experimentally:

• Run appropriate molecular weight markers alongside samples

• Include positive control lysates (e.g., BxPC-3 cells) known to express CHST10

• Consider performing deglycosylation experiments to assess contribution of glycans to apparent molecular weight

• Use multiple antibody clones targeting different epitopes to confirm specificity

• Perform knockout/knockdown validation to confirm band identity

When analyzing experimental results, researchers should acknowledge this known discrepancy in their methods and results sections, particularly when presenting data to audiences unfamiliar with CHST10 characteristics.

What are the optimal sample preparation methods for CHST10 detection?

Optimal detection of CHST10 requires careful consideration of sample preparation techniques specific to each experimental application:

For Western Blotting:

• Cell lysis should be performed using buffers containing appropriate protease inhibitors to prevent degradation

• For BxPC-3 cells (validated positive control), standard RIPA buffer with complete protease inhibitor cocktail is effective

• Sample denaturation at 95°C for 5 minutes in SDS sample buffer is recommended

• Loading 20-40 μg of total protein per lane typically yields detectable signals

• Running samples on 10-12% SDS-PAGE gels provides optimal resolution around the 57 kDa mark where CHST10 is observed

For Immunohistochemistry:

• Formalin-fixed, paraffin-embedded tissue sections (4-6 μm thickness) are suitable

• Antigen retrieval is crucial, with two validated options:

  • TE buffer at pH 9.0 (primary recommendation)

  • Citrate buffer at pH 6.0 (alternative approach)

• Blocking with 5-10% normal serum in PBS for 1 hour at room temperature reduces background

• Primary antibody incubation at 1:20-1:200 dilution overnight at 4°C

• Human gliomas tissue serves as a validated positive control

For applications analyzing CHST10-modified steroid hormones, specialized chromatography methods have been employed:

• HPLC separation coupled with mass spectrometry has successfully identified sulfated and glucuronidated estradiol in serum from wild-type but not CHST10-null female mice

• Radiolabeled substrates can be used for tracking CHST10 activity in vivo

What controls should be included when working with CHST10 antibodies?

Robust experimental design requires appropriate controls to validate CHST10 antibody specificity and performance:

Positive Controls:

• BxPC-3 cell lysates have been validated for Western blot applications

• Human gliomas tissue has been confirmed positive for immunohistochemistry

• Brain tissue from wild-type mice shows HNK-1 antigen expression (indirect marker of CHST10 activity)

Negative Controls:

• CHST10-null mouse tissues provide excellent negative controls when available

• Primary antibody omission controls help identify non-specific binding of secondary antibodies

• Isotype controls (rabbit IgG at equivalent concentration) assess non-specific binding

• Peptide competition assays, where available, can confirm antibody specificity

Technical Controls:

• Loading controls (β-actin, GAPDH) for Western blotting ensure equal protein loading

• Molecular weight markers to confirm band size (noting the expected 57 kDa vs calculated 42 kDa)

• Cross-validation with multiple antibody clones targeting different epitopes

• Sequential dilution series to establish optimal antibody concentration for each experimental system

Inclusion of these controls enhances data reliability and facilitates troubleshooting when unexpected results occur. Researchers should document all control measures in their methods sections to strengthen the validity of their findings.

How can CHST10 antibodies contribute to steroid hormone research?

CHST10 antibodies provide valuable tools for investigating a novel regulatory mechanism in steroid hormone biology. The discovery that CHST10 sulfates glucuronidated steroid hormones, effectively creating doubly-conjugated hormones with altered receptor binding capacity, opens several research avenues:

• Visualization of steroid hormone processing pathways: Using CHST10 antibodies in conjunction with markers for steroid receptors and glucuronyltransferases can map the cellular components involved in hormone processing and modification.

• Quantification of CHST10 expression in endocrine disorders: Alterations in CHST10 levels may contribute to conditions characterized by hormonal imbalances. For example, given the subfertility phenotype in CHST10-null mice , human reproductive disorders might involve CHST10 dysregulation.

• Mechanistic studies of steroid inactivation: By tracking CHST10 localization and activity using antibodies, researchers can better understand how steroid hormones are regulated within target tissues. The estrogen-response element reporter assays suggest that CHST10-modified estrogen cannot bind its receptor , indicating a potential inactivation mechanism.

• Therapeutic target identification: Understanding CHST10's role in steroid hormone regulation may identify it as a potential therapeutic target for conditions involving hormonal dysregulation.

Methodologically, this research would benefit from combining immunodetection of CHST10 with analytical techniques such as HPLC and mass spectrometry to correlate enzyme levels with modified hormone concentrations . Dual labeling experiments with CHST10 antibodies and steroid receptor antibodies could provide insights into the spatial relationship between hormone processing and receptor availability.

What insights can CHST10 immunostaining provide about neurodevelopment?

CHST10's role in creating the HNK-1 carbohydrate antigen in neurons positions it as a significant factor in neurobiological research. The HNK-1 epitope is involved in neurodevelopment and synaptic plasticity , making CHST10 immunostaining a valuable approach for investigating:

• Neural circuit formation: Tracking CHST10 expression during development may reveal temporal patterns associated with critical periods of circuit establishment. The HNK-1 epitope is carried by glycoproteins and glycolipids in neurons , potentially influencing cell adhesion and migration.

• Synaptic plasticity mechanisms: Previous studies have shown that CHST10-deficient mice exhibit impaired basal synaptic transmission and long-term memory deficits , suggesting CHST10 plays a role in synapse function.

• Neurological disorder models: Given its role in synaptic function, alterations in CHST10 expression or localization may contribute to neurological or neurodevelopmental disorders.

• Comparative neurobiology: The reactivity of CHST10 antibodies across species (human, mouse, rat) facilitates cross-species studies of neuronal development and function.

For immunohistochemical applications, researchers should note that CHST10 antibodies have been validated for use in human gliomas tissue , suggesting utility in both normal and pathological neural tissues. The recommended dilution range for IHC applications (1:20-1:200) provides a starting point for optimization in neurobiological studies. Antigen retrieval with TE buffer (pH 9.0) is recommended, though citrate buffer (pH 6.0) can serve as an alternative .

Combining CHST10 immunostaining with functional assays and behavioral studies in model organisms could establish connections between molecular mechanisms and cognitive or behavioral outcomes.

What are common issues when using CHST10 antibodies and how can they be resolved?

Researchers working with CHST10 antibodies may encounter several technical challenges that require methodological adjustments:

Issue: Discrepancy between observed and predicted molecular weight

The observed molecular weight of CHST10 in Western blotting (57 kDa) differs from its calculated size (42 kDa) . This can cause confusion in band identification.

Resolution:

• Include positive control lysates (e.g., BxPC-3 cells)

• Note this known discrepancy in methods and results sections

• Consider deglycosylation experiments to determine if post-translational modifications contribute to the size difference

Issue: Weak or absent signal in Western blotting

Resolution:

• Optimize antibody concentration within the recommended range (1:500-1:3000)

• Increase protein loading (up to 50-60 μg per lane)

• Extend primary antibody incubation time (overnight at 4°C)

• Ensure transfer efficiency, particularly for higher molecular weight proteins

• Verify sample preparation procedures, including protease inhibitor usage

Issue: High background in immunohistochemistry

Resolution:

• Optimize antibody dilution (starting with 1:100-1:200 range)

• Extend blocking time or increase blocking reagent concentration

• Ensure proper antigen retrieval using recommended buffers (TE buffer pH 9.0 or citrate buffer pH 6.0)

• Include appropriate negative controls (primary antibody omission, isotype controls)

• Consider adding a peroxidase quenching step if using HRP detection systems

Issue: Inconsistent results across different tissue types

Resolution:

• Validate antibody performance in each new tissue type

• Adjust fixation and antigen retrieval conditions based on tissue characteristics

• Consider tissue-specific modifications to blocking solutions to reduce non-specific binding

• Note that CHST10 expression levels may vary naturally across tissues and developmental stages

How should conflicting results with different CHST10 antibody clones be interpreted?

When different antibody clones targeting CHST10 yield conflicting results, systematic investigation is necessary:

• Compare epitope targets: Different antibodies may target distinct regions of CHST10. Antibodies targeting functionally critical domains (e.g., the catalytic domain containing the RDP sequence in exon 5) may provide more functionally relevant information than those targeting non-conserved regions.

• Evaluate validation data: Review the validation information for each antibody, including:

  • Verified samples (e.g., BxPC-3 cells)

  • Knockout/knockdown validation data

  • Cross-reactivity profiles across species

• Cross-validate with orthogonal methods:

  • Confirm CHST10 expression using mRNA detection methods (RT-PCR, RNA-seq)

  • Employ functional assays measuring sulfotransferase activity

  • Use mass spectrometry for protein identification

• Consider isoform specificity: Check if antibodies might be detecting different isoforms or splice variants of CHST10.

• Assess experimental conditions: Different antibodies may perform optimally under specific conditions. Systematically test:

  • Sample preparation methods

  • Dilution ranges

  • Incubation conditions

  • Detection systems

When reporting such conflicts in the literature, researchers should clearly document the clone identifiers, catalog numbers, and detailed methodological conditions to facilitate reproducibility and proper interpretation by the scientific community.

What novel applications of CHST10 antibodies might advance our understanding of sulfotransferase biology?

The emerging understanding of CHST10's dual role in both HNK-1 antigen formation and steroid hormone regulation suggests several innovative research directions:

• Tissue-specific CHST10 regulation: Investigating how CHST10 expression is differentially regulated across tissues could reveal tissue-specific mechanisms for hormone regulation. CHST10 antibodies could enable quantitative immunohistochemistry across multiple tissues to establish expression patterns and correlate them with local hormone activities.

• Developmental dynamics: Tracking CHST10 expression throughout development, particularly during key reproductive and neurological developmental windows, could identify critical periods where sulfotransferase activity shapes developmental trajectories.

• Interplay with other sulfotransferases: CHST10 functions alongside other sulfotransferases like Sult1E1, which also sulfates steroid hormones . Dual immunolabeling studies could map the spatial relationships between these enzymes and identify potential functional redundancies or specializations.

• Disease-associated alterations: Examining CHST10 expression in pathological conditions involving hormonal dysregulation (e.g., polycystic ovary syndrome, endometriosis) or neurological disorders (given CHST10's role in forming the HNK-1 epitope involved in neurodevelopment) could uncover new pathophysiological mechanisms.

• Therapeutic targeting: As understanding of CHST10's role in hormone regulation expands, developing tools to modulate its activity could offer therapeutic approaches for conditions characterized by hormonal imbalances. Antibodies could serve as validation tools for such interventions.

These research directions would benefit from combining CHST10 antibody-based detection with emerging technologies such as spatial transcriptomics, single-cell proteomics, and advanced imaging techniques to build comprehensive models of sulfotransferase function in complex biological systems.

How might different knockout strategies affect interpretation of CHST10 function?

The comparison of different CHST10 knockout approaches reveals important considerations for experimental design and interpretation:

Previous studies targeting the second exon of CHST10 produced viable and fertile mice with cognitive deficits , while more recent work targeting exon 5 (containing the RDP sequence in the catalytic domain) resulted in stronger phenotypes including subfertility . This difference highlights several methodological considerations:

• Potential dominant negative effects: The exon 5 knockout strategy might produce a truncated protein fragment from exons 1-4 that could function as a dominant negative for other sulfotransferases, potentially explaining the stronger phenotypes observed .

• Functional domain targeting: Since exon 5 encodes the RDP sequence in the catalytic domain , its disruption may more effectively eliminate enzymatic activity compared to targeting other regions.

• Isoform specificity: Different targeting strategies might affect specific isoforms differently, potentially preserving some functions while eliminating others.

For researchers designing CHST10 loss-of-function studies, these observations suggest:

• Carefully selecting targeting strategies based on structural and functional domains

• Including detailed molecular characterization of the resulting mutants (RNA and protein)

• Considering potential compensatory mechanisms by related sulfotransferases

• Comparing phenotypes across multiple targeting strategies when possible

• Complementing knockout approaches with specific enzymatic activity assays